Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance
Cancer Medicine · 2025
DOI: 10.1002/cam4.70827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jingyi Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Brain Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanfang Hospital, Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Non‐small cell lung cancer patients with EGFR mutation have a high rate of brain metastases, and EGFR tyrosine kinase inhibitors (TKIs) are the principal therapeutic approach. However, acquired targeted therapy resistance is the main reason for EGFR‐TKIs' treatment failure. At present, the mechanism of intracranial acquired targeted therapy resistance is limited, mainly due to the lack of a cell line that can be used for its study.
Methods
A brain parenchymal metastatic sample that progressed after third‐generation EGFR‐TKI treatment was used to establish a cell line named AlmoR1. The genetic characteristics of the cell line were evaluated by short tandem repeat (STR) profiling and whole‐exome sequencing analysis. The phenotypic characteristics were characterized by CCK8, western blot, HE staining, immunohistochemistry (IHC), and orthotopic brain tumor model.
Results
The cell line we successfully established, AlmoR1, can be passed in vitro stably. STR analysis revealed it was a novel NSCLC BM cell line. It harbors the EGFR E746_A750del (ex19del) mutation, and the IC50 to almonertinib and osimertinib of AlmoR1 was significantly higher than that of sensitive cells. In our orthotopic brain tumor model construction with AlmoR1 cells, 75% (3/4) tumor formation can be observed in the living system.
Conclusions
These data suggest that the established cell line, AlmoR1, preserved the resistance to broad third‐generation EGFR‐TKIs and good tumorigenicity in an intracranial orthotopic model, so that it can serve as a new tool to elucidate the pathogenesis, explore new treatment methods, and conduct the development of new drugs for targeted therapy resistance of brain metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- Department of Neurosurgery, Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, People's Republic of China.
- Department of Interventional Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
ORCID-Profile: Rong Wang
Förderung
- Nanfang Hospital
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Wu, J., Wu, X., Wang, J., Feng, G., Wang, Y., Chen, Z., Wang, W., & Wang, R. (2025). Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance. Cancer Medicine. https://doi.org/10.1002/cam4.70827
Vancouver
Wu J, Wu X, Wang J, Feng G, Wang Y, Chen Z, et al. Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance. Cancer Medicine. 2025. doi:10.1002/cam4.70827
BibTeX
@article{Wu2025,
author = {Wu, Jingyi and Wu, Xiangfei and Wang, Jing and Feng, Guili and Wang, Yuhan and Chen, Zide and Wang, Wei and Wang, Rong},
title = {Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR ‐ TKI Resistance},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70827}
}
EUVIMED